title: Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
abstract: OBJECTIVE
  Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HBOC) have an increased risk of developing ovarian cancer. The only effective strategy to reduce this risk is a risk reducing salpingo-oophorectomy (RRSO). The aim of this study was to evaluate the short-term surgical outcome and safety of a RRSO.
  
  
  METHODS
  Included were all consecutive women with a BRCA1/2 mutation or members of a HBOC family who visited our Family Cancer Clinic between September 1995 and March 2006, and choose for RRSO.
  
  
  RESULTS
  159 women were included, of which 97 (61.0%) BRCA1 and 32 (20.1%) BRCA2 mutation carriers, and 30 women of a HBOC family (18.9%). The median age at RRSO was 42.9 years (30.3-61.1) in the BRCA1 group, 48.4 years (33.5-66.9) in the BRCA 2 group and 46.4 (32.8-68.7) years in the HBOC group (p=0.02). The median body mass index (BMI) was 24.9 kg/m(2), 30.1% were overweighed (BMI 25-30) and 18.7% were obese (BMI>30). The RRSO was performed by primary laparoscopy (n=154) or laparotomy (n=5). Intraoperatively, one (0.6%) major complication occurred and laparoscopy was converted to laparotomy. In one patient (0.6%) a minor complication occurred. Post-operatively five minor complications (3.1%) were observed. Median hospital stay was 1 day (0-13 days).
  
  
  CONCLUSIONS
  Laparoscopic RRSO in BRCA1/2 mutation carriers seems to be a safe procedure with a low intraoperative and post-operative complication rate (1.3% and 3.1% respectively), a low conversion rate (0.6%) and a short median hospital stay (1.0 day).
authors.affiliation: Department of Gynaecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: M J A
authors.initials: MJ
authors.lastname: Kenkhuis
authors.forename: G H
authors.initials: GH
authors.lastname: de Bock
authors.forename: P Oude
authors.initials: PO
authors.lastname: Elferink
authors.forename: H J G
authors.initials: HJ
authors.lastname: Arts
authors.forename: J C
authors.initials: JC
authors.lastname: Oosterwijk
authors.forename: L
authors.initials: L
authors.lastname: Jansen
authors.forename: M J E
authors.initials: MJ
authors.lastname: Mourits
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics; D005187:Fallopian Tubes / Q000601:surgery*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D007902:Length of Stay; D008875:Middle Aged; D009154:Mutation; D009765:Obesity / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000517:prevention & control*; D010052:Ovariectomy / Q000009:adverse effects / Q000379:methods; D011183:Postoperative Complications; D016896:Treatment Outcome